Pelthos Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PTHS NYSE American 2836 pelthos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pelthos Therapeutics Inc.

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - Jan 13th, 2026 6:30 am
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Jan 5th, 2026 5:30 am
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn - Dec 23rd, 2025 3:57 pm
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% - Dec 4th, 2025 5:00 am
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - Dec 2nd, 2025 6:00 am
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results - Nov 13th, 2025 4:45 am
LGND: Target Up On Improved Growth Outlook - Nov 10th, 2025 8:05 am
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - Nov 7th, 2025 6:00 am
Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 - Nov 5th, 2025 6:00 am
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum - Oct 9th, 2025 6:00 am
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free - Sep 16th, 2025 6:00 am
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences - Sep 8th, 2025 6:30 am
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference - Sep 2nd, 2025 6:00 am
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update - Aug 18th, 2025 6:00 am
Sector Update: Health Care Stocks Rise Late Afternoon - Jul 10th, 2025 1:57 pm
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum - Jul 10th, 2025 6:00 am
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Jul 2nd, 2025 5:00 am
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - Jul 2nd, 2025 5:00 am